Tuesday, February 14, 2012

Half of Crohn's Patients on Humira in Remission Up to 3 Years: Study

(DG News) UPDATED 2010-03-04
According to a new study, about half of patients with moderate to severe Crohn's disease in the trial who took Humira (adalimumab) and responded well to it remained in remission for up to three years. Two-thirds of the patients who took the drug for the three-year period experienced adverse events, 30 percent of which were serious.  Read full story >
See all Inflammatory Bowel Disease News

People who read this also read...